GlobeNewswire

Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors
11/03/2026
Company Also Announces New Name: Quantum Cyber and Change in Nasdaq Ticker symbol BERKELEY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ) , a molecular genetics diagnostic company [...]
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
11/03/2026
Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combination Phase 2 trial of denifanstat/resmetirom combination in F4 MASH patients planned to initiate in 2H 2026 Secured global, [...]
Annual General Meeting 2026 – GN Store Nord A/S
11/03/2026
Today, GN Store Nord A/S held its Annual General Meeting. The Annual General Meeting was held in accordance with the agenda announced on February 16, 2026, as set out below. The report by the Board of Directors was [...]
Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth
11/03/2026
2025 Full Year Revenue of $180.5 Million, up 12% Year-over-Year; Adjusted EBITDA of $42.0 Million, up 23% Year-over-Year ; Net Income of $20.2 Million, up 40% Year-over-Year Company Affirms 2026 Annual Guidance of $200 [...]
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
11/03/2026
Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is planned for Q2 2026, with topline data anticipated in 2H 2027 BURLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- [...]
Beyond Air to Participate in the 38th Annual Roth Conference in March
11/03/2026
GARDEN CITY, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of [...]
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
11/03/2026
– Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease – NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- Arvinas [...]
NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data
11/03/2026
Agreement further extends NetraMark’s portfolio of AI-driven projects in depression and central nervous system (CNS) disorders TORONTO, March 11, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “ [...]
Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of Series A to $100 Million to Advance Potential First-in-Class Oral Therapy for Dystonia and Parkinson’s Disease
11/03/2026
New $40 million raise brings Series A total to $100M, enabling advancement of VIM0423, a first-in-class oral therapeutic, into Phase 2 trials for isolated dystonia and for Parkinson’s disease First person has been dosed [...]
Lighter. Cheaper. Funner. Pub Light Is Here.
11/03/2026
Pub Beer introduces a 99‑calorie American‑style light lager at 4% ABV BEND, Ore., March 11, 2026 (GLOBE NEWSWIRE) -- Pub Beer , the Cheap Fun beer brand by Tilray Brands, Inc . (Nasdaq: TLRY; TSX: TLRY), today announced [...]
UREVO Launched "Train Hard, Recover Smart" Campaign to Redefine Smart Recovery
11/03/2026
Encouraging Sports Enthusiasts to Move Better Through Smarter Recovery New York, March 11, 2026 (GLOBE NEWSWIRE) -- Throughout February this year, smart wellness innovator UREVO launched its new campaign "Train Hard, [...]
Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy
11/03/2026
Company Reports Record Revenue and Profitability for Full-Year 2025 REHOVOT, Israel and HOBOKEN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company [...]
CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering
11/03/2026
ZUG, Switzerland and BOSTON, March 11, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced the pricing of $550 million aggregate principal amount of its convertible senior [...]
UREVO Launched "Train Hard, Recover Smart" Campaign to Redefine Smart Recovery
11/03/2026
NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Throughout February this year, smart wellness innovator UREVO launched its new campaign, " Train Hard, Recover Smart ," encouraging sports enthusiasts worldwide to take a [...]
GT Biopharma to Participate in the 38th Annual Roth Conference
11/03/2026
SAN FRANCISCO, CALIFORNIA, March 11, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the [...]
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
11/03/2026
Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights into clinically meaningful changes in HAE attack symptoms, and support for hierarchical ranking of RAPIDe-3 endpoints ZUG [...]
Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates
11/03/2026
Platform Rebrand of Researgency.ai; First Purpose-Built AI Agent for Biotech Expected to Ship Within Two Weeks ARLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) announces that it is [...]
Commit Biologics appoints serial biotech founder as new CEO to take complement-powered immune engagers into the clinic
11/03/2026
Dr. Thomas L. F. Montgomery Andresen joins from T-Cypher Bio Follows breakthrough non-human primate data demonstrating deep B-cell depletion without cytokine release Commit is poised to nominate its first two clinical [...]
Bavarian Nordic and Serum Institute of India Expand Strategic Partnership with Chikungunya Vaccine Manufacturing Agreement
11/03/2026
The agreement enables a full tech transfer of the chikungunya vaccine for future supply to low- and middle-income countries. Expanded collaboration provides future co-development opportunities. COPENHAGEN, Denmark, [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum